Literature DB >> 32557594

Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study.

Sherif S Awad1, Ahmed A Touni1, Manal Y Gabril2.   

Abstract

BACKGROUND: Vitiligo is a depigmentary skin disfigurement resulting from destruction of melanocytes caused by a possible malfunctioning immunity. This destruction could be linked to an aberrant T-cell-mediated immune response. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1) are immune checkpoints capable of downregulating T-cell immune functions.
OBJECTIVES: To evaluate the pattern of expression of PD-1 and CTLA-4 in active vitiligo skin.
METHODS: Thirty nonsegmental vitiligo (NSV) patients had been included in this pilot study. Marginal, lesional, and nonlesional skin biopsies were obtained. PD-1 and CTLA-4 immunohistochemistry expression in the mononuclear inflammatory infiltrates were evaluated using digital images.
RESULTS: The marginal and lesional inflammatory infiltrates were significantly abundant when compared to nonlesional ones. The marginal infiltrates were significantly abundant when compared to the lesional ones. PD-1 and CTLA-4 were significantly expressed in the marginal and lesional infiltrates when compared to nonlesional skin. Moreover, the marginal expression of PD-1 was significantly higher than the lesional expression. However, no similar significant difference in CTLA-4 expression was found between the marginal and lesional infiltrates. Significant positive correlations were found between the expressions of PD-1 and CTLA-4 in marginal and lesional infiltrates.
CONCLUSION: Programmed death-1 and CTLA-4 are expressed within the inflammatory infiltrate of active NSV. Further studies are required to confirm their significance in the development or limitation of the disease.
© 2020 the International Society of Dermatology.

Entities:  

Mesh:

Year:  2020        PMID: 32557594     DOI: 10.1111/ijd.14983

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors.

Authors:  Adam P Curnock; Giovanna Bossi; Jyothi Kumaran; Lindsay J Bawden; Rita Figueiredo; Rajeevkumar Tawar; Katherine Wiseman; Emma Henderson; Sec Julie Hoong; Veronica Gonzalez; Hemza Ghadbane; David Eo Knight; Ronan O'Dwyer; David X Overton; Christina M Lucato; Nicola Mg Smith; Carlos R Reis; Keith Page; Lorraine M Whaley; Michelle L McCully; Stephen Hearty; Tara M Mahon; Peter Weber
Journal:  JCI Insight       Date:  2021-10-22

Review 2.  Targeting the PD-1/PD-L1 Axis in Human Vitiligo.

Authors:  Marcella Willemsen; Cornelis J M Melief; Marcel W Bekkenk; Rosalie M Luiten
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.